Avalia Immunotherapies is developing a vaccine and immunotherapy platform to improve clinical outcomes for patients with cancer and infectious disease. The company's lead program is targeting a functional cure for chronic hepatitis B.
Company (Alive / Active)
Phone: +64 (0) 21 241 542
69 Gracefield Road
Lower Hutt, 5010
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)